{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:26:01Z","timestamp":1793067961802,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Saudi Pharm. J."],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s44446-025-00038-y","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T11:50:59Z","timestamp":1758714659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9446-2034","authenticated-orcid":false,"given":"Abdulrahman G.","family":"Alharbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"3","key":"38_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2337\/db14-1671","volume":"64","author":"B Ahr\u00e9n","year":"2015","unstructured":"Ahr\u00e9n B (2015) Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes. Diabetes 64(3):715\u2013717","journal-title":"Diabetes"},{"issue":"January","key":"38_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/DMSO.S387116","volume":"16","author":"M Aldawsari","year":"2023","unstructured":"Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M (2023) The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab Syndr Obes 16(January):575\u2013595","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"38_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ejn.14096","volume":"49","author":"D Athauda","year":"2019","unstructured":"Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I et al (2019) Post hoc analysis of the Exenatide-PD trial\u2014Factors that predict response. Eur J Neurosci 49(3):410\u2013421","journal-title":"Eur J Neurosci"},{"key":"38_CR4","unstructured":"Bansal AB, Patel P, Khalili Y Al. Orlistat. (2024)"},{"key":"38_CR5","doi-asserted-by":"crossref","unstructured":"Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al (2022) The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res [Internet]. 182:106320. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1043661822002651","DOI":"10.1016\/j.phrs.2022.106320"},{"key":"38_CR6","doi-asserted-by":"publisher","unstructured":"Bertoccini L, Baroni MG (2021) GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection. In: Islam MDS (eds). Diabetes: from research to clinical practice: Volume 4 [Internet]. Cham: Springer International Publishing. p. 193\u2013212. Available from: https:\/\/doi.org\/10.1007\/5584_2020_494","DOI":"10.1007\/5584_2020_494"},{"issue":"3","key":"38_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA (2017) Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab 19(3):336\u201347","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"38_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","volume":"29","author":"JB Buse","year":"2007","unstructured":"Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29(1):139\u2013153","journal-title":"Clin Ther"},{"issue":"9683","key":"38_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683):39\u201347","journal-title":"Lancet"},{"key":"38_CR10","unstructured":"BYDUREON\u00ae BCISETM (2017) (exenatide extended-release) injectable suspension, for subcutaneous use [prescribing information]."},{"issue":"6","key":"38_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819\u2013837","journal-title":"Cell Metab"},{"key":"38_CR12","doi-asserted-by":"publisher","first-page":"216179","DOI":"10.1016\/j.canlet.2023.216179","volume":"563","author":"YC Chang","year":"2023","unstructured":"Chang YC, Chan MH, Yang YF, Li CH, Hsiao M (2023) Glucose transporter 4: insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression. Cancer Lett 563:216179","journal-title":"Cancer Lett"},{"issue":"9","key":"38_CR13","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41366-020-0618-3","volume":"44","author":"BSY Choi","year":"2020","unstructured":"Choi BSY, Daoust L, Pilon G, Marette A, Tremblay A (2020) Potential therapeutic applications of the gut microbiome in obesity: from brain function to body detoxification. Int J Obes 44(9):1818\u20131831. https:\/\/doi.org\/10.1038\/s41366-020-0618-3","journal-title":"Int J Obes"},{"issue":"4","key":"38_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/oby.23374","volume":"30","author":"B\u00d8 Christoffersen","year":"2022","unstructured":"Christoffersen B\u00d8, Sanchez-Delgado G, John LM, Ryan DH, Raun K, Ravussin E (2022) Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity 30(4):841\u2013857","journal-title":"Obesity"},{"issue":"11","key":"38_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40265-018-0946-y","volume":"78","author":"AA Coulter","year":"2018","unstructured":"Coulter AA, Rebello CJ, Greenway FL (2018) Centrally acting drugs for obesity: past, present, and future. Drugs 78(11):1113\u20131132","journal-title":"Drugs"},{"key":"38_CR16","doi-asserted-by":"crossref","unstructured":"d\u2019Aquino AI, Maikawa CL, Nguyen LT, Lu K, Hall IA, Jons CK, et al (2023) Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management. Cell Rep Med 4(11)","DOI":"10.1016\/j.xcrm.2023.101292"},{"issue":"1","key":"38_CR17","doi-asserted-by":"publisher","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner R, Murad H, Agay N, Olmer L, Freedman LS (2024) Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open 7(1):e2350408\u2013e2350408","journal-title":"JAMA Netw Open"},{"key":"38_CR18","doi-asserted-by":"crossref","unstructured":"Deacon CF (2019) Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol 10(February).","DOI":"10.3389\/fendo.2019.00080"},{"issue":"3","key":"38_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.endonu.2011.11.007","volume":"59","author":"A Del Prete","year":"2012","unstructured":"Del Prete A, Iadevaia M, Loguercio C (2012) The role of gut hormones in controlling the food intake. What is their role in emerging diseases? Endocrinol Nutr 59(3):197\u2013206","journal-title":"Endocrinol Nutr"},{"key":"38_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.neubiorev.2018.07.017","volume":"94","author":"F Devoto","year":"2018","unstructured":"Devoto F, Zapparoli L, Bonandrini R, Berlingeri M, Ferrulli A, Luzi L et al (2018) Hungry brains: a meta-analytical review of brain activation imaging studies on food perception and appetite in obese individuals. Neurosci Biobehav Rev 94:271\u2013285","journal-title":"Neurosci Biobehav Rev"},{"issue":"9645","key":"38_CR21","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D et al (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372(9645):1240\u20131250","journal-title":"Lancet"},{"issue":"2","key":"38_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2337\/dc09-1499","volume":"33","author":"DJ Drucker","year":"2010","unstructured":"Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB (2010) Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33(2):428\u2013433","journal-title":"Diabetes Care"},{"issue":"3","key":"38_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/hepr.12351","volume":"45","author":"Y Eguchi","year":"2015","unstructured":"Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M et al (2015) Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 45(3):269\u2013278","journal-title":"Hepatol Res"},{"key":"38_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051020","author":"K Errafii","year":"2022","unstructured":"Errafii K, Khalifa O, Al-Akl NS, Arredouani A (2022) Comparative transcriptome analysis reveals that Exendin-4 improves steatosis in HepG2 cells by modulating signaling pathways related to lipid metabolism. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10051020","journal-title":"Biomedicines"},{"key":"38_CR25","unstructured":"Federation WO (2022) London: World Obesity Federation. [cited 2025 Feb 1]. World Obesity Federation. World obesity atlas 2022. Available from: https:\/\/data.worldobesity.org\/publications\/?cat=15"},{"issue":"2","key":"38_CR26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1042\/BST20150244","volume":"44","author":"MM Fletcher","year":"2016","unstructured":"Fletcher MM, Halls ML, Christopoulos A, Sexton PM, Wootten D (2016) The complexity of signalling mediated by the glucagon-like peptide-1 receptor. Biochem Soc Trans 44(2):582\u2013588","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"38_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.toxicon.2010.12.016","volume":"59","author":"BL Furman","year":"2012","unstructured":"Furman BL (2012) The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon 59(4):464\u2013471","journal-title":"Toxicon"},{"issue":"Supplement_2","key":"38_CR28","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.2337\/dc11-s231","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber AJ (2011) Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diabetes Care 34(Supplement_2):S279-84","journal-title":"Diabetes Care"},{"issue":"10193","key":"38_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"10","key":"38_CR30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385(10):896\u2013907","journal-title":"N Engl J Med"},{"key":"38_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/nu17081303","author":"KK Gofron","year":"2025","unstructured":"Gofron KK, Wasilewski A, Ma\u0142gorzewicz S (2025) Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review. Nutrients. https:\/\/doi.org\/10.3390\/nu17081303","journal-title":"Nutrients"},{"key":"38_CR32","doi-asserted-by":"crossref","unstructured":"Granata A, Maccarrone R, Anzaldi M, Leonardi G, Pesce F, Amico F, et al (2022) GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: State of the art. Vol. 15, Clinical Kidney Journal. Oxford University Press p. 1657\u201365.","DOI":"10.1093\/ckj\/sfac069"},{"issue":"9","key":"38_CR33","first-page":"1","volume":"1","author":"K Hamed","year":"2024","unstructured":"Hamed K, Alosaimi MN, Ali BA, Alghamdi A, Alkhashi T, Alkhaldi SS et al (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus 1(9):1\u201317","journal-title":"Cureus"},{"issue":"4","key":"38_CR34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bph.15462","volume":"179","author":"J Helmst\u00e4dter","year":"2022","unstructured":"Helmst\u00e4dter J, Keppeler K, K\u00fcster L, M\u00fcnzel T, Daiber A, Steven S (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits\u2014the role of the GLP-1 receptor. Br J Pharmacol 179(4):659\u2013676","journal-title":"Br J Pharmacol"},{"key":"38_CR35","doi-asserted-by":"publisher","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino Sr RB, Granger CB, Jones NP, et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet [Internet] 392(10157):1519\u201329. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","DOI":"10.1016\/S0140-6736(18)32261-X"},{"issue":"19","key":"38_CR36","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1113\/jphysiol.2009.175067","volume":"587","author":"GM Holmes","year":"2009","unstructured":"Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA (2009) Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol 587(19):4749\u20134759","journal-title":"J Physiol"},{"key":"38_CR37","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-13-0221","author":"C H\u00f6lscher","year":"2014","unstructured":"H\u00f6lscher C (2014) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. https:\/\/doi.org\/10.1530\/JOE-13-0221","journal-title":"J Endocrinol"},{"issue":"4","key":"38_CR38","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409\u20131439","journal-title":"Physiol Rev"},{"issue":"5","key":"38_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/atm.2019.01.09","volume":"7","author":"JJ Holst","year":"2019","unstructured":"Holst JJ (2019) Long-acting glucagon-like peptide-1 receptor agonist\u2014status December 2018. Ann Transl Med 7(5):83\u201383","journal-title":"Ann Transl Med"},{"issue":"2","key":"38_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","volume":"211","author":"JJ Holst","year":"1987","unstructured":"Holst JJ, \u00d8rskov C, Vagn Nielsen O, Schwartz TW (1987) Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211(2):169\u2013174","journal-title":"FEBS Lett"},{"issue":"July","key":"38_CR41","first-page":"1","volume":"13","author":"MM Holter","year":"2022","unstructured":"Holter MM, Saikia M, Cummings BP (2022) Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion. Front Endocrinol 13(July):1\u201314","journal-title":"Front Endocrinol"},{"issue":"4","key":"38_CR42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ (2017) Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 19(4):524\u2013536","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"38_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12933-020-01106-4","volume":"19","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I (2020) Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol 19(1):156","journal-title":"Cardiovasc Diabetol"},{"key":"38_CR44","unstructured":"International Diabetes Federation (2022) Brussels: International Diabetes Federation. [cited 2025 Feb 1]. International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th ed. (IDF)). Available from: https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/"},{"key":"38_CR45","doi-asserted-by":"publisher","first-page":"108737","DOI":"10.1016\/j.diabres.2021.108737","volume":"174","author":"T Karagiannis","year":"2021","unstructured":"Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR et al (2021) GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 174:108737","journal-title":"Diabetes Res Clin Pract"},{"key":"38_CR46","doi-asserted-by":"publisher","first-page":"116471","DOI":"10.1016\/j.bcp.2024.116471","volume":"229","author":"Z Ke","year":"2024","unstructured":"Ke Z, Ma Q, Ye X, Wang Y, Jin Y, Zhao X et al (2024) Peptide GLP-1 receptor agonists: from injection to oral delivery strategies. Biochem Pharmacol 229:116471","journal-title":"Biochem Pharmacol"},{"key":"38_CR47","doi-asserted-by":"crossref","unstructured":"Kelly CA, Sipos JA (2024) Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists. J Clin Endocrinol Metab dgae722","DOI":"10.1210\/clinem\/dgae722"},{"issue":"1","key":"38_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1185\/030079908X253870","volume":"24","author":"DC Klonoff","year":"2008","unstructured":"Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24(1):275\u2013286","journal-title":"Curr Med Res Opin"},{"issue":"September","key":"38_CR49","first-page":"1","volume":"14","author":"F Kong","year":"2023","unstructured":"Kong F, Wu T, Dai J, Zhai Z, Cai J, Zhu Z et al (2023) Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer\u2019s disease models: a systematic review and meta-analysis of preclinical studies. Front Pharmacol 14(September):1\u201323","journal-title":"Front Pharmacol"},{"issue":"8571","key":"38_CR50","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"330","author":"B Kreymann","year":"1987","unstructured":"Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide-1 7\u201336: a physiological incretin in man. Lancet 330(8571):1300\u20131304","journal-title":"Lancet"},{"issue":"6","key":"38_CR51","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","volume":"28","author":"RF Kushner","year":"2020","unstructured":"Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B et al (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity 28(6):1050\u20131061","journal-title":"Obesity"},{"issue":"15","key":"38_CR52","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","volume":"187","author":"CM Kusminski","year":"2024","unstructured":"Kusminski CM, Perez-Tilve D, M\u00fcller TD, DiMarchi RD, Tsch\u00f6p MH, Scherer PE (2024) Transforming obesity: The advancement of multi-receptor drugs. Cell 187(15):3829\u20133853","journal-title":"Cell"},{"issue":"5","key":"38_CR53","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.japh.2023.06.017","volume":"63","author":"JE Lambson","year":"2023","unstructured":"Lambson JE, Flegal SC, Johnson AR (2023) Administration errors of compounded semaglutide reported to a poison control center\u2014Case series. J Am Pharm Assoc 63(5):1643\u20131645","journal-title":"J Am Pharm Assoc"},{"key":"38_CR54","doi-asserted-by":"crossref","unstructured":"Lee YS, Jun HS (2016) Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Vol. 2016, Mediators of Inflammation. Hindawi Limited","DOI":"10.1155\/2016\/3094642"},{"key":"38_CR55","doi-asserted-by":"crossref","unstructured":"Liang L, Su X, Guan Y, Wu B, Zhang X, Nian X (2024) Correlation between intestinal flora and GLP-1 receptor agonist dulaglutide in type 2 diabetes mellitus treatment\u2014A preliminary longitudinal study. iScience [Internet] 27(5):109784. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S258900422401006X","DOI":"10.1016\/j.isci.2024.109784"},{"issue":"8 August","key":"38_CR56","first-page":"1","volume":"18","author":"C Liao","year":"2023","unstructured":"Liao C, Liang X, Zhang X, Li Y (2023) The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis. PLoS ONE 18(8 August):1\u201320","journal-title":"PLoS ONE"},{"key":"38_CR57","unstructured":"(2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. Vol. 54, Drug and Therapeutics Bulletin. BMJ Publishing Group p. 101."},{"issue":"2","key":"38_CR58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1073\/pnas.79.2.345","volume":"79","author":"PK Lund","year":"1982","unstructured":"Lund PK, Goodman RH, Dee PC, Habener JF (1982) Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci 79(2):345\u2013349","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"38_CR59","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","volume":"30","author":"Y Ma","year":"2013","unstructured":"Ma Y, Huang Y, Yan L, Gao M, Liu D (2013) Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res 30(5):1447\u20131457","journal-title":"Pharm Res"},{"issue":"4","key":"38_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18(4):317\u2013332","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"38_CR61","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1210\/en.2011-1864","volume":"153","author":"LW Madsen","year":"2012","unstructured":"Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sj\u00f6gren I, Andersen S et al (2012) GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 153(3):1538\u20131547","journal-title":"Endocrinology"},{"key":"38_CR62","doi-asserted-by":"crossref","unstructured":"Mansoor H, L BA, Morten D, Kathleen D, G EF, R FD et al (2019a) Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England J Med 381(9):841\u201351","DOI":"10.1056\/NEJMc1913157"},{"key":"38_CR63","doi-asserted-by":"publisher","unstructured":"Mansoor H, L BA, Morten D, Kathleen D, G EF, R FD et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England J Med [Internet]. 381(9):841\u201351. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1901118","DOI":"10.1056\/NEJMoa1901118"},{"issue":"19","key":"38_CR64","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"24","key":"38_CR65","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N (2022) GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 146(24):1882\u20131894","journal-title":"Circulation"},{"issue":"9","key":"38_CR66","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1056\/NEJMp1001578","volume":"362","author":"P Mary","year":"2010","unstructured":"Mary P, Curtis R (2010) Weighing risks and benefits of liraglutide \u2014 the FDA\u2019s review of a new antidiabetic therapy. N Engl J Med 362(9):774\u2013777","journal-title":"N Engl J Med"},{"key":"38_CR67","doi-asserted-by":"crossref","unstructured":"Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K (2023) SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep 13(1)","DOI":"10.1038\/s41598-023-42989-z"},{"issue":"1","key":"38_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","volume":"15","author":"AR Meloni","year":"2013","unstructured":"Meloni AR, Deyoung MB, Lowe C, Parkes DG (2013) GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: mechanism and glucose dependence. Diabetes Obes Metab 15(1):15\u201327","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"38_CR69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2018Alessio DA (2022) Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 21(1):169","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"38_CR70","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1530\/EJE-19-0566","volume":"181","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Meier JJ (2019) Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol 181(6):R211\u2013R234","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"38_CR71","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113\u20131124","journal-title":"N Engl J Med"},{"issue":"9","key":"38_CR72","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.peptides.2005.02.016","volume":"26","author":"T Osaka","year":"2005","unstructured":"Osaka T, Endo M, Yamakawa M, Inoue S (2005) Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 26(9):1623\u20131631","journal-title":"Peptides"},{"key":"38_CR73","doi-asserted-by":"crossref","unstructured":"Pang J, Feng JN, Ling W, Jin T (2022) The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs\u2014Therapeutic potential exploration in lung injury. Vol. 12, Acta Pharmaceutica Sinica B. Chinese Academy of Medical Sciences, p. 4040\u201355","DOI":"10.1016\/j.apsb.2022.06.003"},{"key":"38_CR74","doi-asserted-by":"crossref","unstructured":"Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, et al (2020) Improvements to postprandial glucose control in subjects with type 2 diabetes: A multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care 8(1).","DOI":"10.1136\/bmjdrc-2020-001319"},{"issue":"4","key":"38_CR75","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcdemann J, Andreassen C, Navarria A et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6(4):275\u2013286","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"38_CR76","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","volume":"38","author":"P Rossing","year":"2023","unstructured":"Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant 38(9):2041\u20132051","journal-title":"Nephrol Dial Transplant"},{"issue":"April","key":"38_CR77","first-page":"1","volume":"14","author":"R Ruze","year":"2023","unstructured":"Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R et al (2023) Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol 14(April):1\u201323","journal-title":"Front Endocrinol"},{"issue":"3","key":"38_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","volume":"15","author":"M Shah","year":"2014","unstructured":"Shah M, Vella A (2014) Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 15(3):181\u2013187","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"38_CR79","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12974-019-1638-6","volume":"16","author":"Y Shan","year":"2019","unstructured":"Shan Y, Tan S, Lin Y, Liao S, Zhang B, Chen X et al (2019) The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J Neuroinflammation 16(1):242","journal-title":"J Neuroinflammation"},{"issue":"1133","key":"38_CR80","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/postgradmedj-2019-137186","volume":"96","author":"KH Sheahan","year":"2020","unstructured":"Sheahan KH, Wahlberg EA, Gilbert MP (2020) An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J 96(1133):156\u2013161","journal-title":"Postgrad Med J"},{"key":"38_CR81","doi-asserted-by":"crossref","unstructured":"Singh K, Aulakh SK, Nijjar GS, Singh S, Sandhu APS, Luthra S, et al (2024) Rebalancing the gut: glucagon-like peptide-1 agonists as a strategy for obesity and metabolic health. Cureus","DOI":"10.7759\/cureus.64738"},{"issue":"1","key":"38_CR82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7570\/jomes22067","volume":"32","author":"R Sinha","year":"2023","unstructured":"Sinha R, Papamargaritis D, Sargeant JA, Davies MJ (2023) Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. J Obes Metab Syndr 32(1):25\u201345","journal-title":"J Obes Metab Syndr"},{"key":"38_CR83","doi-asserted-by":"crossref","unstructured":"Tian S, Zhou S, Wu W, lin Y, Wang T, Sun H, et al (2025) GLP-1 Receptor agonists alleviate diabetic kidney injury via \u03b2-klotho-mediated ferroptosis inhibition. Adv Sci 12(4).","DOI":"10.1002\/advs.202409781"},{"issue":"4","key":"38_CR84","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bph.15638","volume":"179","author":"S Trapp","year":"2022","unstructured":"Trapp S, Brierley DI (2022) Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. Br J Pharmacol 179(4):557\u2013570","journal-title":"Br J Pharmacol"},{"issue":"8","key":"38_CR85","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018a) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6(8):605\u2013617","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"38_CR86","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018b) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6(8):605\u2013617. https:\/\/doi.org\/10.1016\/S2213-8587(18)30104-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"38_CR87","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1111\/dom.14160","volume":"22","author":"S Verma","year":"2020","unstructured":"Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD et al (2020) Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab 22(12):2487\u20132492","journal-title":"Diabetes Obes Metab"},{"key":"38_CR88","doi-asserted-by":"crossref","unstructured":"Verma S, Bhatta M, Davies M, Deanfield JE, Garvey WT, Jensen C, et al (2023) Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. EClinicalMedicine 55.","DOI":"10.1016\/j.eclinm.2022.101737"},{"issue":"8","key":"38_CR89","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/ijcp.12847","volume":"70","author":"X Xue","year":"2016","unstructured":"Xue X, Ren Z, Zhang A, Yang Q, Zhang W, Liu F (2016) Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. Int J Clin Pract 70(8):649\u2013656","journal-title":"Int J Clin Pract"},{"key":"38_CR90","doi-asserted-by":"crossref","unstructured":"Yaribeygi H, Farrokhi FR, Abdalla MA, Sathyapalan T, Banach M, Jamialahmadi T, et al (2021) The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes. Vol. 2021, Journal of Diabetes Research. Hindawi Limited","DOI":"10.1155\/2021\/6518221"},{"issue":"9309","key":"38_CR91","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and \u03b2-cell function in type 2 diabetes: a parallel-group study. Lancet 359(9309):824\u2013830","journal-title":"Lancet"},{"issue":"14","key":"38_CR92","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1016\/j.cell.2022.05.007","volume":"185","author":"T Zhang","year":"2022","unstructured":"Zhang T, Perkins MH, Chang H, Han W, de Araujo IE (2022) An inter-organ neural circuit for appetite suppression. Cell 185(14):2478-2494.e28","journal-title":"Cell"},{"key":"38_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"38_CR94","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3945\/an.115.008268","volume":"6","author":"H Ziauddeen","year":"2015","unstructured":"Ziauddeen H, Alonso-Alonso M, Hill JO, Kelley M, Khan NA (2015) Obesity and the neurocognitive basis of food reward and the control of intake. Adv Nutr 6(4):474\u2013486","journal-title":"Adv Nutr"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-025-00038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44446-025-00038-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-025-00038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T10:03:18Z","timestamp":1762941798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44446-025-00038-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s44446-025-00038-y","relation":{},"ISSN":["1319-0164","2213-7475"],"issn-type":[{"value":"1319-0164","type":"print"},{"value":"2213-7475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}